Patents by Inventor Carola Leuschner

Carola Leuschner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY/DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20220048951
    Abstract: The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.
    Type: Application
    Filed: October 15, 2021
    Publication date: February 17, 2022
    Applicant: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Carola LEUSCHNER, Hector ALILA
  • METHODS FOR DIAGNOSING LHRH OR hCG/LH RECEPTOR EXPRESSING TUMORS, CANCERS AND NEOPLASIAS
    Publication number: 20210324443
    Abstract: The invention relates to diagnosis, detection, screening, identifying and predicting methods. In various embodiments, methods of the invention include diagnosis, detection, or screening for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject; identifying a subject that will or is likely to respond to a therapy for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia); and predicting therapeutic efficacy of a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) treatment in a subject.
    Type: Application
    Filed: June 29, 2021
    Publication date: October 21, 2021
    Inventors: Carola LEUSCHNER, Hector ALILA
  • Methods for diagnosing LHRH or hCG/LH receptor expressing tumors, cancers and neoplasias
    Patent number: 11066693
    Abstract: The invention relates to diagnosis, detection, screening, identifying and predicting methods. In various embodiments, methods of the invention include diagnosis, detection, or screening for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject; identifying a subject that will or is likely to respond to a therapy for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia); and predicting therapeutic efficacy of a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) treatment in a subject.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: July 20, 2021
    Assignee: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Carola Leuschner, Hector Alila
  • LYTIC-PEPTIDE-HER2/NEU (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) LIGAND CONJUGATES AND METHODS OF USE
    Publication number: 20200353032
    Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.
    Type: Application
    Filed: July 28, 2020
    Publication date: November 12, 2020
    Inventors: Hector ALILA, Carola LEUSCHNER
  • Lytic-peptide-Her2/neu (Human Epidermal growth factor Receptor 2) ligand conjugates and methods of use
    Patent number: 10729740
    Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: August 4, 2020
    Assignee: Esperance Pharmaceuticals, Inc.
    Inventors: Hector Alila, Carola Leuschner
  • ANTIBODY/DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20190367558
    Abstract: The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.
    Type: Application
    Filed: January 11, 2019
    Publication date: December 5, 2019
    Applicant: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Carola LEUSCHNER, Hector ALILA
  • IMMUNE-STIMULATING PEPTIDES AND CHECKPOINT INHIBITORS, AND USES THEREOF FOR TREATING CANCER
    Publication number: 20190241660
    Abstract: Presented herein are immune-stimulating peptides and uses thereof for treating cancer. The immune-stimulating peptides can be used alone, or in combination with checkpoint inhibitors and other anti-cancer therapies. The immune-stimulating peptides can also be used for expanding T-cells in vitro or ex vivo, which expanded T-cells can then be used for adoptive cell therapy.
    Type: Application
    Filed: December 4, 2018
    Publication date: August 8, 2019
    Inventors: Brett P. GIROIR, Clifford H. KERN, III, Carola LEUSCHNER
  • Antibody/drug conjugates and methods of use
    Patent number: 10233214
    Abstract: The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: March 19, 2019
    Assignee: Esperance Pharmaceuticals, Inc.
    Inventors: Carola Leuschner, Hector Alila
  • METHODS FOR DIAGNOSIS OF AND PREDICTING TREATMENT EFFICACY OF HORMONE RECEPTOR EXPRESSING TUMORS, CANCERS AND NEOPLASIAS
    Publication number: 20190040450
    Abstract: The invention relates to diagnosis, detection, screening, identifying and predicting methods. In various embodiments, methods of the invention include diagnosis, detection, or screening for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject; identifying a subject that will or is likely to respond to a therapy for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia); and predicting therapeutic efficacy of a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) treatment in a subject.
    Type: Application
    Filed: October 8, 2018
    Publication date: February 7, 2019
    Inventors: Carola Leuschner, Hector Alila
  • Methods for diagnosis of and predicting treatment efficacy of hormone receptor expressing tumors, cancers and neoplasias
    Patent number: 10093961
    Abstract: The invention relates to diagnosis, detection, screening, identifying and predicting methods. In various embodiments, methods of the invention include diagnosis, detection, or screening for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject; identifying a subject that will or is likely to respond to a therapy for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia); and predicting therapeutic efficacy of a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) treatment in a subject.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: October 9, 2018
    Assignee: ESPERANCE PHARMACEUTICALS
    Inventors: Carola Leuschner, Hector Alila
  • LYTIC-PEPTIDE-HER2/NEU (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) LIGAND CONJUGATES AND METHODS OF USE
    Publication number: 20170157199
    Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 8, 2017
    Applicant: Esperance Pharmaceuticals, Inc.
    Inventors: Hector Alila, Carola Leuschner
  • ANTIBODY/DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20170121370
    Abstract: The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.
    Type: Application
    Filed: November 14, 2016
    Publication date: May 4, 2017
    Applicant: Esperance Pharmaceuticals, Inc.
    Inventors: CAROLA LEUSCHNER, HECTOR ALILA
  • Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
    Patent number: 9586996
    Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: March 7, 2017
    Assignee: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Hector Alila, Carola Leuschner
  • Antibody/drug conjugates and methods of use
    Patent number: 9492563
    Abstract: The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: November 15, 2016
    Assignee: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Carola Leuschner, Hector Alila
  • Lytic domain fusion constructs and methods of making and using same
    Patent number: 9255134
    Abstract: The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: February 9, 2016
    Assignees: Esperance Pharmaceuticals, Inc., Board of Supervisors of Louisana State University and Agricultural and Mechanical College
    Inventors: Carola Leuschner, Hector Alila
  • LYTIC DOMAIN FUSION CONSTRUCTS AND METHODS OF MAKING AND USING SAME
    Publication number: 20140255513
    Abstract: The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.
    Type: Application
    Filed: September 26, 2013
    Publication date: September 11, 2014
    Inventors: Carola Leuschner, Hector Alila
  • FOLLICLE-STIMULATING HORMONE (FSH)/LYTIC DOMAIN FUSION CONSTRUCTS AND METHODS OF MAKING AND USING SAME
    Publication number: 20140161767
    Abstract: The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.
    Type: Application
    Filed: November 14, 2013
    Publication date: June 12, 2014
    Inventors: CAROLA LEUSCHNER, HECTOR ALILA, WILLIAM HANSEL
  • ANTIBODY/DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20140127241
    Abstract: The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.
    Type: Application
    Filed: October 30, 2013
    Publication date: May 8, 2014
    Inventors: CAROLA LEUSCHNER, HECTOR ALILA
  • Lytic domain fusion constructs and methods of making and using same
    Patent number: 8546535
    Abstract: The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.
    Type: Grant
    Filed: March 5, 2009
    Date of Patent: October 1, 2013
    Assignees: Esperance Pharmaceuticals, Inc., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Carola Leuschner, Hector Alila
  • LYTIC-PEPTIDE-HER2/NEU (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) LIGAND CONJUGATES AND METHODS OF USE
    Publication number: 20130157961
    Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.
    Type: Application
    Filed: April 28, 2011
    Publication date: June 20, 2013
    Applicant: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Hector Alila, Carola Leuschner, Martha Juban, Ann Coulter